Hafez: Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study

All Studies Meta Analysis

▶

All Studies Meta Analysis Recent:

Download Image

Hafez, 1,486 patient HCQ late treatment study: 12% faster viral clearance [p=0.59] https://c19p.org/hafez

copied to clipboard

Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study

Hafez et al., Antibiotics, doi:10.3390/antibiotics11040498

8 Apr 2022 Source PDF Share Tweet

Retrospective hospitalized patients in the United Arab Emirates, showing no significant difference in viral clearance with different combinations of HCQ, AZ, favipiravir, and lopinavir/ritonavir.

Important missing comments or errors? Let us know.

viral clearance time, 12.3% lower, HR 0.88, p = 0.59, treatment 40, control 1,446, inverted to make RR<1 favor treatment, Cox proportional hazards.

viral clearance time, 58.7% lower, HR 0.41, p = 0.09, treatment 4, control 1,446, inverted to make RR<1 favor treatment, HCQ + favipiravir + lopinavir/ritonavir, Cox proportional hazards.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Hafez et al., 8 Apr 2022, retrospective, United Arab Emirates, peer-reviewed, 6 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit